Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations

@article{Coe2019BuprenorphinePR,
  title={Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations},
  author={Marion A. Coe and Michelle Lofwall and Sharon L. Walsh},
  journal={Journal of Addiction Medicine},
  year={2019},
  volume={13},
  pages={93–103}
}
&NA; Buprenorphine is an effective treatment for opioid use disorder. As a high-affinity, partial agonist for the mu-opioid receptor, buprenorphine suppresses opioid withdrawal and craving, reduces illicit opioid use, and blocks exogenous opioid effects including respiratory depression. Other pharmacologic benefits of buprenorphine are its superior safety profile compared with full opioid agonists and its long half-life that allows daily or less-than-daily dosing. New and innovative… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
47 Citations
Highly Influential Citations
1
Background Citations
20

47 Citations

Citation Type

Citation Type

Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data
TLDR
The BUP dose in treatment of OUD should be individualized based on a continuous clinical benefit-risk assessment, as there is currently no consensus regarding optimal dose or dose-range of buprenorphine for treatment of opioid use disorder.
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
TLDR
Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.
Perioperative Buprenorphine Management: A Multidisciplinary Approach.
Buprenorphine implants: a model for expedited development and approval of new drugs
TLDR
A review of the long-acting drugs provides compelling evidence to recommend that generic drug-controlled release products may be eligible for alternative regulatory programs.
Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
TLDR
The pharmacology, clinical efficacy and prospects of these medications are discussed.
An overview of buprenorphine prescribing for the advanced practice psychiatric nurse.
TLDR
This review seeks to provide advanced practice psychiatric nurses (APPNs) with an overview of buprenorphine prescribing, with an emphasis on novel, long-acting delivery systems.
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
TLDR
This review aims to systematically review the buprenorphine initiation strategies that have emerged in the last decade and suggests that concomitant administration of small doses of bupenorphine with opioids can avoid the unwanted withdrawal associated with bupreliminary initiation.
Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report
Treatment of Opioid Use Disorder Attributed to Fentanyl With High-Dose Buprenorphine: A Case Report.
TLDR
A case of a patient with opioid use disorder attributed to NPF is presented, successfully inducted onto high-dose buprenorphine/ naloxone while admitted to an inpatient facility and remains engaged in outpatient treatment post-discharge.
Clinical Pearls for Buprenorphine Treatment
TLDR
This guidance intends to serve as a useful resource, particularly in low-resource or rural settings, to empower practitioners in buprenorphine treatment to expand the numbers of prescribers necessary to assist in diminishing the unrelenting opioid crisis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
TLDR
The pharmacokinetic and pharmacodynamic properties of buprenorphine allow it to be a feasible option for substitution therapy in the treatment of opioid dependence.
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
TLDR
Buprenorphine has potential for treating narcotic addiction since it is acceptable to addicts, is long-acting, produces a low level of physical dependence such that patients may be easily detoxified, is less toxic than drugs used for maintenance therapy, and blocks the effects of narcotics.
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
TLDR
It is demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder.
Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial
TLDR
The results support the use of this depot formulation for treatment initiation and stabilization of patients with OUD, with the further benefit of obviating the risk for misuse and diversion of daily buprenorphine while retaining its therapeutic benefits.
Pharmacokinetics of Buprenorphine: A Comparison of Sublingual Tablet Versus Liquid after Chronic Dosing
TLDR
A randomized, double-blind, crossover study with dose increases was conducted to determine steady state buprenorphine plasma levels for the 2 formulations and to assess the relative bioavailability of each.
Buprenorphine: new pharmacological aspects.
  • A. Cowan
  • Biology, Medicine
    International journal of clinical practice. Supplement
  • 2003
TLDR
Interest in buprenorphine spanning more than 30 years has been attributed to its unique pharmacological characteristics, including moderate intrinsic activity, high affinity to and slow dissociation from mu-opioid receptors.
Buprenorphine: a (relatively) new treatment for opioid dependence.
TLDR
Buprenorphine, a partial mu-opoid receptor agonist, has unique pharmacologic properties that distinguish it from methadone and other medications used in the treatment of opioid dependence and is generally safe and well-tolerated.
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
TLDR
Investigation of buprenorphine pharmacokinetics by different routes of administration at dosages approximating those used in opioid-dependence studies found that the terminal elimination half-life of norbuprenorphines was longer than bupenorphine and the mean peak plasma concentrations were less than 1 ng/mL.
Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
TLDR
Among persons with opioid dependence, the use of buprenorphine implants compared with placebo resulted in less opioid use over 16 weeks as assessed by urine samples and a greater change on clinician global ratings of severity of opioid dependence.
...
1
2
3
4
5
...